Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...

Along with VX-880, it is also working on encapsulated islet cells as a treatment for T1D, although that programme remains in preclinical development. Encapsulation could mean doing away with the ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are ...

Julien Grogg, PhD, MBA - CEO of Release Therapeutics Release Tx logo Dr. Julien Grogg will Lead the Company's Transition to Clinical ...